Consistent Revenue GrowthSustained revenue growth across 2020–2025 indicates expanding market penetration and product acceptance. Durable top-line expansion supports scale economics, funds capacity investments and exports, and provides a multi-month runway to absorb shocks while financing strategic initiatives.

Solid Gross And EBIT MarginsStable gross and EBIT margins reflect efficient manufacturing and cost control, especially important in complex dosage forms. Margin resilience supports long-term cash generation and reinvestment capacity, enabling sustained competitiveness even if net margins fluctuate.

Focus On Injectable FormulationsA strategic focus on parenteral injectables creates higher technical barriers, pricing power and differentiated contract-manufacturing opportunities. This product mix supports durable revenue streams, export potential and stronger margins relative to commoditised oral generics over months to years.

Bears Say

Inconsistent Free Cash FlowVolatile free cash flow and episodes of negative FCF weaken the company's ability to self-fund capex, working capital and debt service. Over a 2–6 month horizon this constrains flexibility, raises refinancing risk and can force tradeoffs between growth and balance sheet repair.

Moderately High LeverageA moderately high debt-to-equity ratio increases fixed obligations and financial risk. With leverage elevated, interest and principal servicing can pressure free cash flows and limit capital allocation for expansion or R&D during downturns, reducing strategic optionality.

Earnings Volatility / EPS DeclineSignificant EPS decline and net margin variability suggest earnings quality and cost control issues or episodic charges. Persistent volatility undermines forecasting, raises execution risk for investments, and reduces confidence in sustained profitability over the medium term.

Gufic Biosciences Limited News

Gufic Biosciences Settles SEBI Compliance Penalties Over Independent Director Appointment

Gufic Biosciences Limited ( ($IN:GUFICBIO) ) has shared an update. Gufic Biosciences has disclosed that stock exchanges BSE...

4d ago

Gufic Biosciences to Appeal GST Penalty Order, Sees No Material Impact

Gufic Biosciences Limited ( ($IN:GUFICBIO) ) has provided an update. Gufic Biosciences Limited has disclosed that it received...

3M ago

Gufic Biosciences Releases Earnings Call Audio

Gufic Biosciences Limited ( ($IN:GUFICBIO) ) has shared an announcement. Gufic Biosciences Limited announced that the audio recording...

4M ago

Gufic Biosciences Schedules Analyst and Investor Meeting

The latest update is out from Gufic Biosciences Limited ( ($IN:GUFICBIO) ). Gufic Biosciences Limited has announced a...

4M ago

GUFICBIO FAQ

What was Gufic Biosciences Limited’s price range in the past 12 months?

Gufic Biosciences Limited lowest stock price was ₹268.65 and its highest was ₹409.00 in the past 12 months.

What is Gufic Biosciences Limited’s market cap?

Gufic Biosciences Limited’s market cap is ₹28.37B.

When is Gufic Biosciences Limited’s upcoming earnings report date?

Gufic Biosciences Limited’s upcoming earnings report date is May 29, 2026 which is in 73 days.

How were Gufic Biosciences Limited’s earnings last quarter?

Gufic Biosciences Limited released its earnings results on Feb 13, 2026. The company reported ₹1.239 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.239.

Is Gufic Biosciences Limited overvalued?

According to Wall Street analysts Gufic Biosciences Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Gufic Biosciences Limited pay dividends?

Gufic Biosciences Limited pays a Annually dividend of ₹0.1 which represents an annual dividend yield of 0.03%. See more information on Gufic Biosciences Limited dividends here

What is Gufic Biosciences Limited’s EPS estimate?

Gufic Biosciences Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Gufic Biosciences Limited have?

Gufic Biosciences Limited has 100,282,510 shares outstanding.

What happened to Gufic Biosciences Limited’s price movement after its last earnings report?

Gufic Biosciences Limited reported an EPS of ₹1.239 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.022%.

Which hedge fund is a major shareholder of Gufic Biosciences Limited?

Currently, no hedge funds are holding shares in IN:GUFICBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Gufic Biosciences Limited

Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products to more than 20 countries. The company was founded in 1970 and is based in Mumbai, India.